Verana Health®

DATASHEET
Multiple Myeloma



Qdata® Multiple Myeloma is an exclusive dataset providing a clear view of how patients are treated over time, including lines of therapy, transplant decisions, and outcomes in the real world.

Verana Health® powers oncology research with high-quality real-world data sourced from curated electronic health records and linked data sources at leading cancer centers across the US. Built specifically for cancer research, Verana Health's oncology datasets and analytics deliver clinically rich insights across tumor types and lines of therapy, supporting evidence generation at every stage of the drug development and commercialization lifecycle.

Abstracted Data

ABSTRACTED	ACCESSIBLE	ABSTRACTED + ACCESSIBLE
17,670	23,800+	41,470+

Potential patients as of Q3 2026

Note: Abstracted data is available for immediate delivery. Accessible data requires additional curation.

Clinician-led and AI-enabled oncology data platform

Verana Health securely ingests, links, and curates raw oncology care data from point-of-care clinical encounters. Purpose-built, fit-for-purpose data is designed to support rigorous research and confident decision-making across the oncology lifecycle.

Ingest Data
Structured and unstructured oncology EHR data are captured and de-identified, preserving clinical nuance from real-world care delivery.

Link Data
Data are harmonized and tokenized across EHR systems and linked with complementary sources, including claims data, biomarker and genomic data, and other relevant clinical inputs.

Curate Data
Data are clinically abstracted, quality-controlled, and continuously curated using expert oncology oversight and technology.

Curated, High-Quality Oncology Data
Available across multiple tumor types and treatment settings, including:

Hematologic cancers:
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndrome
- Small Lymphocytic Lymphoma
- Mantle Cell Lymphoma

Solid tumor cancers:
- Breast Cancer
- Colon Cancer
- Rectal Cancer
- Gastric Cancer
- Lung Cancer
- Melanoma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer

Verana Health®

DATASHEET
Multiple Myeloma

Abstracted Data Summary:

DATA SET QUALITY

5.1 yrs	Average length of follow-up
28.2	Performance statuses on avg. per patient
78%	Patients with performance Status
96%	Patients with race data
93%	Patients with ethnicity data

TREATMENT HIGHLIGHTS

Triple Class Exposed	6,863
Autologous Transplant	8,156
Allogeneic Transplant	296
CAR-T Cell Therapy	884
Received BCL-2 or BTK Inhibitor	378
2+ LOT	10,444
3+ LOT	6,761

TOP DISEASE SUBTYPES

Kappa Free Light Chain	17,194
Lambda Free Light Chain	17,166
Del17p/mutation in TP53	2,264

About Verana Health

Verana Health, Inc.® is a digital health company revolutionizing patient care and clinical research by utilizing physician expertise and artificial intelligence to unlock the true potential of real-world data. With exclusive access to the world's largest patient data sources in oncology, ophthalmology, neurology, and urology. Verana Health is powering real-world evidence generation. Clinicians utilize these insights to improve the quality of care and quality of life for patients, and life sciences companies rely on the insights to accelerate the development of new therapies. For more information, visit www.veranahealth.com.

© 2026 Verana Health | Datasheet | Multiple Myeloma | October 2026